The SME IPO space remains active in early 2026, with nutraceutical and wellness-focused companies gaining increasing investor interest. One such upcoming issue is Accretion Nutraveda IPO, which is drawing attention as investors closely monitor the Accretion Nutraveda IPO GMP (Grey Market Premium) to assess demand ahead of listing.
In this detailed IPO analysis, we cover the Accretion Nutraveda IPO GMP, issue size, price band, key dates, lot size, and an overall IPO review to help investors make informed decisions.
Accretion Nutraveda IPO Overview
Accretion Nutraveda IPO is a book-built issue with a total size of ₹24.77 crore. The IPO is entirely a fresh issue of 0.19 crore equity shares, indicating that the funds raised will be used to support business expansion, operational requirements, and future growth plans.
Key IPO Highlights
IPO Size ₹24.77 crore
Fresh Issue 0.19 crore shares
Issue Type Book Build Issue
Listing Platform BSE SME
Accretion Nutraveda IPO Important Dates
Here are the key dates investors should note
IPO Open Date January 28, 2026
IPO Close Date January 30, 2026
Allotment Date (Expected) February 2, 2026
Listing Date (Tentative) February 4, 2026
Accretion Nutraveda IPO Price Band & Lot Size
The Accretion Nutraveda IPO price band has been fixed at ₹122 to ₹129 per share.
Investment Details
Price Band ₹122 – ₹129 per share
Lot Size 1,000 shares
Retail Investor Investment
Minimum Application 2 lots (2,000 shares)
Minimum Investment ₹2,58,000 (at upper price band)
HNI Investment
Minimum Application 3 lots (3,000 shares)
Minimum Investment ₹3,87,000
The relatively high minimum investment amount suggests that the IPO may attract investors with a higher risk appetite.
Accretion Nutraveda IPO GMP (Grey Market Premium)
The Accretion Nutraveda IPO GMP reflects unofficial trading activity in the grey market before the IPO listing. Investors track GMP closely to gauge short-term demand and possible listing performance.
Understanding IPO GMP
Positive GMP Indicates strong investor interest
Low or Flat GMP Signals cautious sentiment
Negative GMP Reflects weak demand
It is important to remember that IPO GMP is unofficial and speculative. GMP can fluctuate daily and should not be considered a guaranteed indicator of listing gains.
Accretion Nutraveda IPO Review Strengths & Risks
Key Strengths
Operates in the nutraceutical and wellness segment, a growing industry
100% fresh issue, highlighting a growth-focused capital strategy
Book-built issue allows efficient price discovery
Potential Risks
SME stocks often face lower liquidity post-listing
Higher minimum investment increases capital risk for retail investors
Listing performance may not always align with GMP trends
Should You Track Accretion Nutraveda IPO GMP
Tracking the Accretion Nutraveda IPO GMP today can help short-term investors understand market sentiment before listing. However, GMP should always be evaluated along with the company’s fundamentals, business model, and overall market conditions.
Long-term investors should focus more on operational strength, revenue visibility, and industry growth potential rather than relying solely on grey market signals.
FAQs on Accretion Nutraveda IPO GMP
Q1. What is Accretion Nutraveda IPO GMP
Accretion Nutraveda IPO GMP refers to the grey market premium at which the IPO shares trade unofficially before listing. It indicates investor sentiment but is not an official price.
Q2. When does Accretion Nutraveda IPO open and close
The IPO opens on January 28, 2026, and closes on January 30, 2026.
Q3. What is the price band of Accretion Nutraveda IPO
The price band is fixed at ₹122 to ₹129 per share.
Q4. What is the minimum investment required for retail investors
Retail investors must apply for 2,000 shares, requiring a minimum investment of ₹2,58,000 at the upper price band.
Q5. On which exchange will Accretion Nutraveda IPO be listed
The IPO will list on the BSE SME platform, with a tentative listing date of February 4, 2026.
Q6. Is Accretion Nutraveda IPO GMP reliable for investment decisions
IPO GMP is unofficial and speculative. It should only be used as a reference and not as the sole basis for investment decisions.
Final Thoughts
The Accretion Nutraveda IPO GMP is gaining attention as the IPO approaches its opening date. While grey market trends can offer early insights, investors should carefully evaluate the risks, investment size, and broader market conditions before subscribing.
Disclaimer This content is for informational purposes only and does not constitute investment advice.
Post a Comment